Targeted nanoparticles deliver siRNA to melanoma

Journal of Investigative Dermatology

Volumn 130, Issue 12, 2010, Pages 2790-2798

  Chen, Yunching ^a   Bathula, Surendar R ^a   Yang, Qi ^a   Huang, Leaf ^a  

^a University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2 DIOLEOYL 3 TRIMETHYLAMMONIOPROPANE; ARGININE DERIVATIVE; N,N DISTEARYL N METHYL N 2 (N' ARGINYL)AMINOETHYLAMMONIUM CHLORIDE; NANOPARTICLE; PACLITAXEL; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; SIGMA OPIATE RECEPTOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 78149467932     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.222     Document Type: Article

References (41)

1. Alshamsan A, Hamdy S, Samuel J et al. (2010) The induction of tumor apoptosis in B16 melanoma following STAT3 siRNA delivery with a lipid-substituted polyethylenimine. Biomaterials 31:1420-8
2. Amarzguioui M, Peng Q, Wiiger MT et al. (2006) Ex vivo and in vivo delivery of anti-tissue factor short interfering RNA inhibits mouse pulmonary metastasis of B16 melanoma cells. Clin Cancer Res 12:4055-61
3. Atallah E, Flaherty L (2005) Treatment of metastatic malignant melanoma. Curr Treat Options Oncol 6:185-93
4. Banerjee R, Tyagi P, Li S et al. (2004) Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 112:693-700
5. Bucci B, D'Agnano I, Amendola D et al. (2005) Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins. Clin Cancer Res 11:2756-67
6. Cejas P, Casado E, Belda-Iniesta C et al. (2004) Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control 15:707-19
7. Ciardiello F, Tortora G (2002) Inhibition of bcl-2 as cancer therapy. Ann Oncol 13:501-2
8. Cui Z, Han SJ, Vangasseri DP et al. (2005) Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm 2:22-8
9. Dang CV, O'Donnell KA, Zeller KI et al. (2006) The c-Myc target gene network. Semin Cancer Biol 16:253-64
10. Devi GR (2006) siRNA-based approaches in cancer therapy. Cancer Gene Ther 13:819-29
11. Evans C, Morrison I, Heriot AG et al. (2006) The correlation between colorectal cancer rates of proliferation and apoptosis and systemic cytokine levels; plus their influence upon survival. Br J Cancer 94:1412-9
12. Fest T, Mougey V, Dalstein V et al. (2002) c-MYC overexpression in Ba/F3 cells simultaneously elicits genomic instability and apoptosis. Oncogene 21:2981-90
13. Gatti G, Maresca G, Natoli M et al. (2009) MYC prevents apoptosis and enhances endoreduplication induced by paclitaxel. PLoS One 4:e5442
14. Greco C, D'Agnano I, Vitelli G et al. (2006) c-MYC deregulation is involved in melphalan resistance of multiple myeloma: role of PDGF-BB. Int J Immunopathol Pharmacol 19:67-79
15. Hersey P (2006) Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma. Curr Opin Oncol 18:189-96
16. Hong J, Zhao Y, Huang W (2006) Blocking c-myc and stat3 by E. coli expressed and enzyme digested siRNA in mouse melanoma. Biochem Biophys Res Commun 348:600-5
17. Jun HS, Park T, Lee CK et al. (2007) Capsaicin induced apoptosis of B16-F10 melanoma cells through down-regulation of Bcl-2. Food Chem Toxicol 45:708-15
18. Lebedeva IV, Washington I, Sarkar D et al. (2007) Strategy for reversing resistance to a single anticancer agent in human prostate and pancreatic carcinomas. Proc Natl Acad Sci USA 104:3484-9
19. Li D, Ueta E, Kimura T et al. (2004) Reactive oxygen species (ROS) control the expression of Bcl-2 family proteins by regulating their phosphorylation and ubiquitination. Cancer Sci 95:644-50
20. Li SD, Chen YC, Hackett MJ et al. (2008a) Tumor-targeted delivery of siRNA by self-assembled nanoparticles. Mol Ther 16:163-9
21. Li SD, Chono S, Huang L (2008b) Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 16:942-6
22. Liu Y, Tao J, Li Y et al. (2009) Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth. Mol Ther 17:269-77
23. Mannava S, Grachtchouk V, Wheeler LJ et al. (2008) Direct role of nucleotide metabolism in C-MYC-dependent proliferation of melanoma cells. Cell Cycle 7:2392-400
24. Mates JM, Sanchez-Jimenez FM (2000) Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int J Biochem Cell Biol 32:157-70
25. Mathieu V, Le Mercier M, De Neve N et al. (2007) Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol 127:2399-410
26. Morris MJ, Cordon-Cardo C, Kelly WK et al. (2005) Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer. Appl Immuno-histochem Mol Morphol 13:6-13
27. Nesbit CE, Tersak JM, Prochownik EV (1999) MYC oncogenes and human neoplastic disease. Oncogene 18:3004-16
28. Pelicano H, Carney D, Huang P (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7:97-110
29. Rae JM, Creighton CJ, Meck JM et al. (2007) MDA-MB-435 cells are derived from M14 melanoma cells\a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 104:13-9
30. Ryan JJ, Prochownik E, Gottlieb CA et al. (1994) c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 91:5878-82
31. Sonoke S, Ueda T, Fujiwara K et al. (2008) Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res 68:8843-51
32. Sulaimon SS, Kitchell BE (2003) The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. J Vet Intern Med 17:760-72
33. Tas F, Argon A, Camlica H et al. (2005) Temozolomide in combination with cisplatin in patients with metastatic melanoma: a phase II trial. Melanoma Res 15:543-8
34. Thannickal VJ, Fanburg BL (2000) Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol 279:L1005-28
35. Tuma RS (2008) Reactive oxygen species may have antitumor activity in metastatic melanoma. J Natl Cancer Inst 100:11-2
36. Vannini I, Bonafe M, Tesei A et al. (2007) Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine. Cell Oncol 29:279-87
37. Villares GJ, Zigler M, Wang H et al. (2008) Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 68:9078-86
38. Wierstra I, Alves J (2008) The c-myc promoter: still MysterY and challenge. Adv Cancer Res 99:113-333
39. Zamora-Avila DE, Zapata-Benavides P, Franco-Molina MA et al. (2009) WT1 gene silencing by aerosol delivery of PEI-RNAi complexes inhibits B16-F10 lung metastases growth. Cancer Gene Ther 16:892-9
40. Zhang XD, Wu JJ, Gillespie S et al. (2006) Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin. Clin Cancer Res 12:1355-64
41. Zhuang D, Mannava S, Grachtchouk V et al. (2008) C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells. Oncogene 27:6623-34